Molecular Testing in Indeterminate Thyroid Nodules: Genomic Landscape, Diagnostic Performance, and Integrated Risk-Stratified Management.

Molecular testing has become an increasingly important adjunct in the evaluation of cytologically indeterminate thyroid nodules. These tests analyze genetic alterations associated with thyroid tumorigenesis, including point mutations, gene fusions, and gene expression profiles, with the aim of refining preoperative risk assessment and reducing unnecessary diagnostic surgery. Despite these advances, the clinical utility of molecular testing remains highly dependent on the context in which results are interpreted. Molecular alterations do not consistently correlate with tumor aggressiveness, and several mutations are observed in both benign and malignant thyroid lesions. In addition, the predictive performance of molecular tests is strongly influenced by the baseline prevalence of malignancy, which varies across clinical settings and is shaped by diagnostic thresholds and patient selection. This commentary summarizes the molecular landscape of thyroid tumors, the diagnostic performance of current molecular testing platforms, and their role in clinical decision-making. Emphasis is placed on the interpretation of molecular findings within a broader diagnostic framework that incorporates cytologic morphology, ultrasound-based risk stratification, and clinical context. A selective, risk-adapted approach to molecular testing may provide the most effective strategy for optimizing patient management while minimizing unnecessary intervention.